Skip to main content
Protalix BioTherapeutics, Inc. logo

Protalix BioTherapeutics, Inc. — Investor Relations & Filings

Ticker · PLX ISIN · US74365A3095 LEI · 549300SDVB3GP4XDFM60 US Manufacturing
Open in API
Filings indexed 950 across all filing types
Latest filing 2023-06-28 Proxy Solicitation & In…
Country US United States of America
Listing US PLX

About Protalix BioTherapeutics, Inc.

https://protalix.com/

Protalix BioTherapeutics, Inc. is a biopharmaceutical company that develops, produces, and commercializes recombinant therapeutic proteins. The company's unique selling point is its proprietary ProCellEx® platform, a plant cell-based protein expression system used to manufacture complex proteins. This technology supports the development of treatments for rare and orphan diseases. Protalix has successfully brought enzyme replacement therapies to market and maintains a pipeline of product candidates targeting conditions with high unmet medical needs. The company's capabilities cover the entire process from protein candidate selection and genetic engineering of plant cells through preclinical and clinical development to commercial-scale production and marketing.

Recent filings

Filing Released Lang Actions
DEFA14A
Proxy Solicitation & Information Statement Classification · 95% confidence The document is a Schedule 14A filing, which is a Proxy Statement related to shareholder voting matters. It announces the adjournment of the Annual Meeting of Stockholders and urges shareholders to vote on a specific proposal regarding an amendment to the Certificate of Incorporation. The content focuses on solicitation of votes and meeting adjournment rather than presenting the actual proxy statement or detailed meeting materials. The document length is short (2697 characters) and it serves as additional materials related to the proxy process. Therefore, it fits best under the category of Proxy Solicitation & Information Statement (PSI).
2023-06-28 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce unscheduled material events or corporate changes. The text mentions a press release about an upcoming investor event and includes a letter to stockholders. There are no financial statements or detailed financial data presented. The document is short (3941 characters) and primarily serves as a notification of an event and a press release. It does not contain an annual report, earnings release, or other detailed financial or management reports. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-05-30 English
ARS
Annual Report
2023-05-19 English
DEF 14A
Proxy Solicitation & Information Statement
2023-05-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about the company's cash position and a milestone payment triggered by FDA approval. It does not contain comprehensive financial statements or detailed financial analysis typical of an earnings release or annual/interim report. The document length is 4322 characters, which is relatively short and mainly serves as an announcement of recent events and a press release. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-05-18 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The text includes a press release about FDA approval of a drug, attached as an exhibit. There are no financial statements or detailed financial data presented, nor is this an annual or quarterly report. The document is short (3329 characters) and primarily serves as an announcement of a significant event. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous filings that do not fit other specific categories.
2023-05-10 English

Browse filings by year

31 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.